Publications by authors named "N Woolacott"
Brain and spinal stimulation therapies for phantom limb pain: a systematic review.
Health Technol Assess
November 2018
Article Synopsis
- Many existing treatments for phantom limb pain (PLP) lack strong evidence and clear management guidelines, prompting a need for systematic reviews of neurostimulation therapies.
- The study aimed to evaluate various brain and spinal stimulation therapies' effectiveness for chronic PLP, considering both invasive (like deep brain and spinal cord stimulation) and non-invasive methods (like rTMS and tDCS).
- Findings indicated that while rTMS showed promise for short-term PLP relief, better evidence for invasive therapies is necessary, as no RCTs were found for them.
The Centre for Reviews and Dissemination and Centre for Health Economics Technology Assessment Group at the University of York was commissioned by the National Institute for Health and Care Excellence (NICE) Highly Specialised Technologies (HST) programme to act as the independent Evidence Review Group (ERG) for an appraisal of Strimvelis, a gene therapy treatment for adenosine deaminase deficiency-severe combined immunodeficiency (ADA-SCID). This paper describes the manufacturing company's submission of clinical and economic evidence, the ERG's review and the resulting NICE guidance. For Strimvelis compared with haematopoietic stem cell transplant (HSCT) from a matched unrelated donor (MUD) and HSCT from a haploidentical donor, the company base-case deterministic incremental cost-effectiveness ratios (ICERs) were £36,360 and £14,645 per quality-adjusted life-year (QALY) gained, respectively (using a discount rate of 1.
View Article and Find Full Text PDFThe National Institute for Health and Care Excellence (NICE) invited the company that manufactures ceritinib (Zykadia, Novartis) to submit evidence on the clinical and cost effectiveness of the drug, as a first-line treatment for adults with anaplastic lymphoma kinase (ALK)-positive (+) advanced non-small-cell lung cancer (NSCLC), as part of the Institute's single technology appraisal (STA) process. The CRD (Centre for Reviews and Dissemination) and CHE (Centre for Health Economics) Technology Assessment Group at the University of York was commissioned to act as the Evidence Review Group (ERG). This paper describes the Company's submission (CS), the ERG review and NICE's subsequent decisions.
View Article and Find Full Text PDFPurpose: To identify the tools that have been used to measure quality of life in hyperhidrosis research and obtain patient insight on commonly used tools.
Methods: Twelve databases were searched to identify studies that reported measuring quality of life or described a quality of life tool in the context of hyperhidrosis. Data on the use of the tools were tabulated and hyperhidrosis-specific and dermatology-specific measures were summarized.